RWM
DNLI icon

Rialto Wealth Management’s Denali Therapeutics DNLI Stock Holding History

Rialto Wealth Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96 Sell
5
-3
-38% -$60 ﹤0.01% 1666
2025
Q4 		$133 Buy
8
+6
+300% +$101 ﹤0.01% 1593
2025
Q3 		$30 Hold
2
– – ﹤0.01% 1690
2025
Q2 		$28 Buy
+2
New +$28 ﹤0.01% 1672

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rialto Wealth Management's DNLI Position: Q1 2026 in Review

Rialto Wealth Management reduced its Denali Therapeutics (DNLI) stake by 38% in Q1 2026, selling an estimated $60 and leaving 5 shares worth $96. The position accounts for ﹤0.01% of the portfolio, ranked #1666.

Rialto Wealth Management first reported a position in DNLI in Q2 2025 and has held it in 4 quarters since. The position peaked at $133 in Q4 2025. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Rialto Wealth Management held 5 shares of Denali Therapeutics worth $96 as of Q1 2026.
  • Rialto Wealth Management sold 3 Denali Therapeutics shares in Q1 2026, an estimated $60.
  • Denali Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q1 2026, its #1666 holding.
  • Rialto Wealth Management first reported a position in Denali Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Rialto Wealth Management's Denali Therapeutics position peaked at $133 in Q4 2025.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.